uploads/2018/03/ambulance-1822457_960_720.jpg

Analyst Ratings for BioTelemetry and Its Peers in March 2018

By

Updated

Company overview

BioTelemetry (BEAT) provides monitoring services and digital population health management for healthcare providers, medical device manufacturing, and centralized core laboratory services for clinical research. The company has developed a proprietary integrated patient management platform that incorporates a wireless data transmission network.

In July 2017, BioTelemetry acquired LifeWatch, a supplier of mobile cardiac monitoring solutions. The acquisition is expected to help BioTelemetry create a comprehensive connected healthcare platform and deliver solutions in the market more effectively.

Article continues below advertisement

Analysts’ recommendations

Of the seven analysts covering BioTelemetry in March 2018, two analysts have given the stock a “strong buy” rating, and five have given it a “buy.” The mean rating for the stock is 1.7 with a target price of $44.17.

Peer ratings

Of the 24 analysts covering Cerner (CERN) in March 2018, 11 of them have given the stock a “buy” or higher rating, and 13 have given it a “hold.” The mean rating for the stock is 2.3 with a target price of $71.75.

Of the nine analysts covering Cross Country Healthcare (CCRN) in March 2018, three analysts have given the stock a “buy” or higher rating, and six have given it a “hold.” The mean rating for the stock is 2.6 with a target price of $12.79.

Of the 20 analysts covering Illumina (ILMN) in March 2018, 14 of them have given the stock a “buy” or higher rating. Five analysts have given it a “hold,” and one has given it a “sell.” The mean rating for the stock is 2.0 with a target price of $257.60.

In the next part of this series, we’ll take a look at BioTelemetry’s segments.

Advertisement

More From Market Realist